Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 15/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530761 | 1.00 | ITGB3 (0.56) | ITGB3ITGA2BTDP1LPAR3LPAR1 | |
| SCHEMBL25363677 | 0.90 | TDP1 (0.51) | ITGB3ITGA2BTDP1LPAR3LPAR1 | |
| SCHEMBL30530754 | 0.87 | ITGB3 (0.66) | ITGB3ITGA2B | |
| SCHEMBL25365464 | 0.87 | ITGB3 (0.66) | ITGB3ITGA2B | |
| SCHEMBL25365852 | 0.85 | ITGB3 (0.45) | ITGB3ITGA2BTDP1LPAR3LPAR1 | |
| SCHEMBL311850 | 0.78 | KDM4E (0.71) | TDP1KDM4EALOX15TSHRSIRT1 | |
| SCHEMBL29676908 | 0.78 | KDM4E (0.71) | TDP1KDM4EALOX15TSHRSIRT1 | |
| SCHEMBL25364471 | 0.77 | GHSR (0.39) | ITGB3ITGA2BLPAR3LPAR1ITGAV | |
| SCHEMBL15939257 | 0.76 | ITGB3 (0.50) | ITGB3ITGA2BKDM4EALOX15TSHR | |
| SCHEMBL30530774 | 0.76 | ITGB3 (0.41) | ITGB3ITGA2BLPAR3LPAR1ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |